Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia
Lancet, J E, Gojo, I, Burton, M, Quinn, M, Tighe, S M, Kersey, K, Zhong, Z, Albitar, M X, Bhalla, K, Hannah, A L, Baer, M R
Published in Leukemia (01.04.2010)
Published in Leukemia (01.04.2010)
Get full text
Journal Article
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials
Potts, B C, Albitar, M X, Anderson, K C, Baritaki, S, Berkers, C, Bonavida, B, Chandra, J, Chauhan, D, Cusack, Jr, J C, Fenical, W, Ghobrial, I M, Groll, M, Jensen, P R, Lam, K S, Lloyd, G K, McBride, W, McConkey, D J, Miller, C P, Neuteboom, S T C, Oki, Y, Ovaa, H, Pajonk, F, Richardson, P G, Roccaro, A M, Sloss, C M, Spear, M A, Valashi, E, Younes, A, Palladino, M A
Published in Current cancer drug targets (01.03.2011)
Published in Current cancer drug targets (01.03.2011)
Get more information
Journal Article